UniteLabs
A vendor-agnostic 'Operating System' for life science laboratories that connects hardware and software through a standardized connectivity layer to enable AI-driven automation.
- CEO / Founder
- Robert Zechlin
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- €3.15M
- Latest Round
- Pre-Seed (€2.77M)
- Key Investors
- Cavalry Ventures, Acurio Ventures, PUSH, LANA Ventures, OMA Business Angels
Technology & Products
Key Products
["UniteLabs Connector (SiLA 2-based integration layer)","Workflow Designer (Modular, drag-and-drop automation orchestrator)","Lab-as-Code Environment (Python SDK for programmatic lab control)","UniteLabs Trust (Study management platform for CRO-client collaboration)","Connector Development Kit (CDK) (Open-source tool for custom device integration)"]
Technological Advantage
Leverages the SiLA 2 (Standardization in Lab Automation) protocol to provide deep, firmware-level access to hardware, combined with a 'Lab-as-Code' approach that allows scientists to treat physical lab processes like software deployments.
Differentiation
Value Proposition
Eliminates vendor lock-in and data silos by providing a universal software layer that reduces lab automation setup time from months to weeks through standardized, bidirectional connectivity.
How They Differentiate
UniteLabs differentiates through a vendor-agnostic 'Operating System' approach based on the SiLA 2 (Standardization in Lab Automation) open protocol. Unlike proprietary vendor software, it offers a 'Lab-as-Code' Python SDK, allowing researchers to programmatically control hardware and integrate instruments from different brands (e.g., Tecan, Hamilton) into a single unified workflow.
Market & Competition
Target Customers
Biotech startups, global pharmaceutical companies, R&D facilities, and non-clinical Contract Research Organizations (CROs).
Industry Verticals
["Biotechnology","Pharmaceuticals","Life Sciences R&D","Medical Diagnostics","Laboratory Automation"]
Competitors
Biosero (Green Button Go), Artificial, HighRes Biosolutions (Cellario), Synthace
Growth & Milestones
Growth Metrics
Expanded operations from Basel to Munich; Team size grown to 11-50 employees; Transitioned from project-based integrations to a scalable platform-as-a-service (PaaS) model.
Major Milestones
["Founded in 2017 as a spin-off from ETH Zürich and University of Basel","Became a core contributor and driver of the SiLA 2 international communication standard","Opened a second major office in Munich, Germany to tap into the local biotech ecosystem","Successfully closed a €2.77M Pre-Seed funding round in April 2024 to scale the connectivity platform"]
Notable Customers
Roche, Lonza, Global Pharmaceutical Companies, Non-clinical Contract Research Organizations (CROs)